Therapeutic potentials of CRISPR-Cas genome editing technology in human viral infections.
Biomed Pharmacother
; 148: 112743, 2022 Apr.
Article
en En
| MEDLINE
| ID: mdl-35228065
Viral infections are a common cause of morbidity worldwide. The emergence of Coronavirus Disease 2019 (COVID-19) has led to more attention to viral infections and finding novel therapeutics. The CRISPR-Cas9 system has been recently proposed as a potential therapeutic tool for the treatment of viral diseases. Here, we review the research progress in the use of CRISPR-Cas technology for treating viral infections, as well as the strategies for improving the delivery of this gene-editing tool in vivo. Key challenges that hinder the widespread clinical application of CRISPR-Cas9 technology are also discussed, and several possible directions for future research are proposed.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Virosis
/
Terapia Genética
/
Sistemas CRISPR-Cas
/
Edición Génica
Límite:
Humans
Idioma:
En
Revista:
Biomed Pharmacother
Año:
2022
Tipo del documento:
Article
País de afiliación:
Irán
Pais de publicación:
Francia